Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
5.17M
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
15.2M
-
Shares change
-
+533K
-
Total reported value, excl. options
-
$153M
-
Value change
-
+$5.5M
-
Number of buys
-
32
-
Number of sells
-
-11
-
Price
-
$10.09
Significant Holders of CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) as of Q3 2022
71 filings reported holding CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share as of Q3 2022.
CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.2M shares
.
Largest 10 shareholders include Saba Capital Management, L.P. (1.21M shares), HIGHBRIDGE CAPITAL MANAGEMENT LLC (1.09M shares), MARSHALL WACE, LLP (849K shares), Periscope Capital Inc. (752K shares), D. E. Shaw & Co., Inc. (748K shares), HSBC HOLDINGS PLC (729K shares), JANUS HENDERSON GROUP PLC (650K shares), Polar Asset Management Partners Inc. (600K shares), FIR TREE CAPITAL MANAGEMENT LP (501K shares), and HGC Investment Management Inc. (500K shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.